Mersana Therapeutics Inc Quick Ratio (MRSN) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mersana Therapeutics inc   (NASDAQ: MRSN)

Mersana Therapeutics Inc 's Quick Ratio

MRSN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2025, Quick Ratio deteriorated to 1.3 below Mersana Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 296 other companies have achieved higher Quick Ratio than Mersana Therapeutics Inc in third quarter 2025. While Quick Ratio total ranking has improved so far during the Q3 2025 to 1251, from total ranking in the second quarter 2025 at 1256.

Explain Quick Ratio?
How much Cash & cash equivalents MRSN´s has?
What are MRSN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRSN Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change -36.65 % -4.58 % 8.9 % -1.85 % 0.54 %
Y / Y Cash & cash equivalent Change -28.5 % 30.47 % 36.05 % -38.27 % -57.66 %
Quick Ratio MRQ 1.3 1.3 1.76 1.73 1.15
MRSN's Total Ranking # 1251 # 1256 # 1038 # 628 # 1458
Seq. Current Liabilities Change -27.08 % 2.02 % -6.88 % -8.55 % 9.84 %
Seq. Cash & cash equivalent Change -26.74 % -24.75 % -5.07 % 36.62 % 33.68 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 297
Healthcare Sector # 524
Overall Market # 1251


Quick Ratio Statistics
High Average Low
12.99 3.84 0.95
(Jun 30 2020)   (Jun 30 2024)




Financial Statements
Mersana Therapeutics Inc 's Current Liabilities $ 43 Millions Visit MRSN's Balance sheet
Mersana Therapeutics Inc 's Cash & cash equivalent $ 56 Millions Visit MRSN's Balance sheet
Source of MRSN's Sales Visit MRSN's Sales by Geography


Cumulative Mersana Therapeutics Inc 's Quick Ratio

MRSN's Quick Ratio for the trailling 12 Months

MRSN Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -9.82 % 0.44 % -3.38 % -15.02 % -22.11 %
Y / Y Cash & cash equivalent TTM Growth -11.41 % -26.09 % -38.4 % -47.62 % -31.6 %
Quick Ratio TTM 1.54 1.47 1.39 1.3 1.57
Total Ranking TTM # 3824 # 2981 # 2902 # 2004 # 3238
Seq. Current Liabilities TTM Growth -10.08 % -1.13 % 1.93 % -0.48 % 0.15 %
Seq. Cash & cash equivalent TTM Growth -6.14 % 5.17 % 8.45 % -17.24 % -21.7 %

Quick ratio ranking by company, industry and sector >> Back to MRSN Financial Strength Comparisons >> Go to Compare MRSN Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Mersana Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Mersana Therapeutics Inc 's Quick Ratio to 1.54, Quick Ratio remained below MRSN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 464 other companies have achieved higher Quick Ratio than Mersana Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2981 to 3824.

Explain Quick Ratio?
How much Cash & cash equivalents MRSN´s has?
What are MRSN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 465
Healthcare Sector # 945
Within the Market # 3824


trailing twelve months Quick Ratio Statistics
High Average Low
9.85 3.78 1.3
(Dec 31 2020)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Spero Therapeutics Inc   3.56 $ 48.616  Millions$ 13.649  Millions
Prelude Therapeutics Inc  3.55 $ 54.957  Millions$ 15.463  Millions
Arcus Biosciences Inc   3.54 $ 831.000  Millions$ 235.000  Millions
Capricor Therapeutics inc   3.50 $ 98.566  Millions$ 28.148  Millions
Cytomx Therapeutics Inc   3.50 $ 143.626  Millions$ 41.029  Millions
Tvardi Therapeutics Inc   3.34 $ 36.460  Millions$ 10.927  Millions
Kyntra Bio Inc   3.28 $ 117.975  Millions$ 35.973  Millions
Immunoprecise Antibodies Ltd   3.23 $ 11.983  Millions$ 3.705  Millions
Arrowhead Pharmaceuticals Inc   3.20 $ 692.818  Millions$ 216.286  Millions
Bolt Biotherapeutics Inc   3.20 $ 31.910  Millions$ 9.966  Millions
Elicio Therapeutics Inc   3.16 $ 20.611  Millions$ 6.515  Millions
Tempest Therapeutics Inc   3.16 $ 7.514  Millions$ 2.378  Millions
Can fite Biopharma Ltd   3.13 $ 8.540  Millions$ 2.731  Millions
Pasithea Therapeutics Corp   3.08 $ 4.123  Millions$ 1.338  Millions
Nuvectis Pharma inc   3.08 $ 35.442  Millions$ 11.502  Millions
Briacell Therapeutics Corp   3.07 $ 10.176  Millions$ 3.318  Millions
Biomea Fusion Inc   3.00 $ 46.642  Millions$ 15.565  Millions
Bridgebio Pharma Inc   2.98 $ 645.942  Millions$ 216.600  Millions
Adagene Inc   2.96 $ 74.524  Millions$ 25.172  Millions
Insmed Inc  2.93 $ 1,679.986  Millions$ 573.689  Millions
Ardelyx inc   2.91 $ 242.705  Millions$ 83.389  Millions
Gossamer Bio Inc   2.90 $ 180.224  Millions$ 62.117  Millions
Damora Therapeutics Inc   2.90 $ 7.606  Millions$ 2.623  Millions
Lipella Pharmaceuticals Inc   2.89 $ 1.856  Millions$ 0.642  Millions
Cadrenal Therapeutics Inc  2.85 $ 3.860  Millions$ 1.353  Millions
Clearside Biomedical Inc   2.85 $ 6.801  Millions$ 2.386  Millions
Kiniksa Pharmaceuticals International Plc  2.85 $ 352.102  Millions$ 123.592  Millions
Proqr Therapeutics N v   2.85 $ 103.503  Millions$ 36.334  Millions
Madrigal Pharmaceuticals Inc   2.84 $ 1,109.749  Millions$ 390.323  Millions
Geovax Labs Inc   2.75 $ 5.009  Millions$ 1.824  Millions

Date modified: 2026-09-26T07:38:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.